Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.58 |
| ▸ | MCHR2 | Q969V1 | 7/20 | 0.57 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7382222 | 0.85 | MCHR2 (0.62) | SIGMAR1MCHR2MCHR1FFAR1 | |
| SCHEMBL3810405 | 0.84 | FFAR1 (0.67) | MCHR2MCHR1FFAR1 | |
| SCHEMBL4223160 | 0.83 | SIGMAR1 (0.51) | SIGMAR1MCHR2FFAR1 | |
| SCHEMBL1586959 | 0.83 | MCHR2 (0.61) | SIGMAR1MCHR2MCHR1FFAR1 | |
| SCHEMBL4408710 | 0.83 | MCHR2 (0.61) | SIGMAR1MCHR2MCHR1FFAR1 | |
| SCHEMBL1587467 | 0.83 | MCHR2 (0.61) | SIGMAR1MCHR2MCHR1FFAR1 | |
| SCHEMBL15160320 | 0.82 | MCHR2 (0.57) | SIGMAR1MCHR2MCHR1FFAR1 | |
| SCHEMBL8243511 | 0.81 | ALDH1A1 (0.49) | SIGMAR1FFAR1 | |
| SCHEMBL3812702 | 0.81 | MCHR2 (0.65) | MCHR2MCHR1FFAR1 | |
| SCHEMBL4233729 | 0.80 | CYP2D6 (0.55) | MCHR2MCHR1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883816-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546417-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | PURDUE PHARMA L.P. (US) | 2012-12-06 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193208-B2 | Fused and spirocycle compounds and the use thereof | PURDUE PHARMA L.P. (US) | 2012-06-05 | — | — | US | disclosed |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | EURO-CELTIQUE S.A. (LU) | 2009-05-07 | — | — | US | disclosed |
| EP-1943250-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007028638-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007028638-A1 | FUSED AND SPIROCYCLE COMPOUNDS AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309778-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | SIGMAR1 220/4885MCHR2 3111/4885MCHR1 2727/4885 |
| US-20090118319-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | SIGMAR1 220/4885MCHR2 3111/4885MCHR1 2727/4885 |
| US-20140045875-A1 | Fused and Spirocycle Compounds and the Use Thereof | CACNA1A, CACNA1E, CACNA1C | SIGMAR1 220/4885MCHR2 3111/4885MCHR1 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.